Singapore markets closed
Straits Times Index
3,205.14 +16.64 (+0.52%) Nikkei
28,804.85 +96.27 (+0.34%) Hang Seng
26,126.93 +109.40 (+0.42%) FTSE 100
7,204.55 +14.25 (+0.20%) BTC-USD
61,100.29 -1,857.77 (-2.95%) CMC Crypto 200
1,453.34 -49.69 (-3.31%)
VCPlus Limited (43E.SI)
SES - SES Delayed Price. Currency in SGD
Add to watchlist
0.02500.0000 (0.00%)
At close: 1:46PM SGT
| Previous close | 0.0250 |
| Open | 0.0250 |
| Bid | 0.0250 x 0 |
| Ask | 0.0260 x 0 |
| Day's range | 0.0250 - 0.0250 |
| 52-week range | 0.0060 - 0.0360 |
| Volume | 3,247,300 |
| Avg. volume | 8,404,498 |
| Market cap | 113.474M |
| Beta (5Y monthly) | 2.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0020 |
| Earnings date | 26 Feb 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease (CD).
© 2021 Verizon Media. All rights reserved.
